Standard BioTools (NASDAQ:LAB) Announces Earnings Results

Standard BioTools (NASDAQ:LAB) issued its earnings results on Tuesday. The company reported $0.03 EPS for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.05, FiscalAI reports. Standard BioTools had a negative return on equity of 7.57% and a net margin of 100.36%. The firm had revenue of $19.39 million for the quarter, compared to the consensus estimate of $18.80 million.

Standard BioTools Stock Up 0.1%

LAB stock traded up $0.00 during trading hours on Tuesday, hitting $0.61. The company’s stock had a trading volume of 1,265,622 shares, compared to its average volume of 2,294,128. The stock has a 50 day moving average price of $0.68 and a two-hundred day moving average price of $0.92. Standard BioTools has a 12 month low of $0.59 and a 12 month high of $1.72. The company has a market capitalization of $241.09 million, a PE ratio of 2.78 and a beta of 1.36.

Analyst Ratings Changes

Separately, Weiss Ratings downgraded Standard BioTools from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, August 7th. Two research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Standard BioTools currently has a consensus rating of “Reduce” and a consensus price target of $1.35.

Standard BioTools Company Profile

Standard BioTools Inc (NASDAQ: LAB) develops and supplies technologies, instruments and consumables used by researchers and biopharmaceutical companies to analyze biological systems. Its portfolio supports applications in proteomics, genomics, single-cell analysis, mass cytometry and spatial biology.

The company’s offerings include the SomaScan protein profiling platform, which measures large numbers of proteins from biological samples, as well as CyTOF mass cytometry systems for high-dimensional single-cell analysis.